

-मिसिल स.- 8(140)/2025/डी.पी/एनपीपीए-डीवी-II

F. No. 8(140)/2025/DP/NPPA-Div. II

कार्यवाहीस. : 272/140/2025/F

Proceeding No: 272/140/2025/F

Minutes of the 272nd (overall) and 140th meeting of the Authority under DPCO, 2013 held on 27.11.2025 at 11.30 AM.

The 272nd meeting of the Authority (overall), which is the 140th meeting under the DPCO, 2013 was held on 27th November, 2025 at 11.30 AM under the Chairmanship of Shri P. Krishnamurthy, Chairman, NPPA. The following Authority members were present during the meeting:

- (i) Ms. Sai Ahlladini Panda, Member Secretary, NPPA
- (ii) Shri Manmohan Sachdeva, Additional Chief Adviser Cost (ACAC), O/o Chief Adviser (Cost), Department of Expenditure

Shri Ranga Chandrashekar, Joint Drug Controller, CDSCO, Ministry of Health & Family Welfare.

The following officers of NPPA attended the meeting and assisted the Authority in its deliberations:

- (i) Shri Sanjay Kumar, Advisor (Cost)
- (ii) Ms. Rashmi Tahiliani, Director (Pricing)
- (iii) Shri Mahaveer Saini, Deputy Director (Pricing)
- (iv) Ms. Yuvika Panwar, Assistant Director (Pricing)
- (v) Shri Bhiva Ram Yadav, Assistant Director (Pricing)

1. Agenda item no. 1 - Confirmation of Minutes of the 139th Meeting held on 14.11.2025.

1.1 The Authority confirmed the minutes of the meeting without any change.

2. Agenda item no. 2 - Action Taken Report on decisions taken by NPPA in its 139th Meeting held on 14.11.2025.

2.1 Noted.

3. Agenda item no. 3 - Status of New Drug applications.

3.1 Noted.



4. Agenda item no. 4 – New Drug applications for price fixation under Paragraph 5 and 15 of DPCO, 2013.

4.1 The Authority deliberated on 11 (Eleven) cases of retail price fixation of new drugs as presented in Agenda no. 4 (1) to 4 (11) falling under the purview of paragraph 2(1)(u) of DPCO, 2013. The Authority approved the retail prices of 11 (Eleven) new drugs under paragraph 5 and 15 of the DPCO, 2013 as given in **Table 1 below.**

Table No. 1: Retail price fixation of new drugs

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1	Bisoprolol Fumarate & Telmisartan Tablets	Each uncoated bilayered tablet contains: Bisoprolol Fumarate IP 2.5 mg Telmisartan IP 40 mg	1 Tablet	M/s Windlas Biotech Ltd./ M/s Intas Pharmaceuticals Ltd.	10.49
2	Bisoprolol Fumarate & Telmisartan Tablets	Each uncoated bilayered tablet contains: Bisoprolol Fumarate IP 5 mg Telmisartan IP 40 mg	1 Tablet	M/s Windlas Biotech Ltd./ M/s Intas Pharmaceuticals Ltd.	12.09
3	Ceftriaxone & Sulbactam for Injection	Each vial contains: Ceftriaxone Sodium IP Eq. to Ceftriaxone 250 mg Sulbactam Sodium IP Eq. to Sulbactam 125 mg	1 vial	M/s Innova Captab Ltd./ M/s Dr. Reddys Laboratories Ltd.	65.30
4	Ceftriaxone & Sulbactam for Injection	Each vial contains: Ceftriaxone Sodium IP Eq. to Ceftriaxone 500 mg Sulbactam Sodium IP Eq. to Sulbactam 250 mg	1 vial	M/s Innova Captab Ltd./ M/s Dr. Reddys Laboratories Ltd.	104.32
5	Ceftriaxone, Disodium Edetate & Sulbactam powder for solution for infusion	Each vial contains: Ceftriaxone Sodium IP (Sterile) Eq. to Ceftriaxone 1000 mg Disodium Edetate IP 37 mg Sulbactam Sodium IP (Sterile) Eq. to Sulbactam 500 mg	1 vial	M/s Gufic Biosciences Ltd./ M/s Criticare Division LLP	567.13
6	Ceftriaxone, Disodium Edetate & Sulbactam powder for solution for infusion	Each vial contains: Ceftriaxone Sodium IP (Sterile) Eq. to Ceftriaxone 2000 mg Disodium Edetate IP 74 mg Sulbactam Sodium IP (Sterile) Eq. to Sulbactam 1000 mg	1 vial	M/s Gufic Biosciences Ltd./ M/s Criticare Division LLP	1140.26


[Signature]

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
7	Levocetirizine Dihydrochloride & Montelukast Sodium Syrup	Each 5 ml of Syrup contains: Levocetirizine Dihydrochloride IP 2.5 mg Montelukast Sodium IP Eq. to Montelukast 4 mg	1 ml	M/s East African (I) Overseas / M/s SRK Puremed LLP	1.48
8	Telmisartan & Amlodipine Tablets	Each uncoated bilayered tablet contains: Telmisartan IP 80 mg Amlodipine Besylate IP eq. to Amlodipine 5 mg	1 Tablet	M/s Unison Pharmaceuticals Pvt. Ltd.	16.00
9	Telmisartan & Hydrochlorothiazide Tablets	Each uncoated bilayered tablet contains: Telmisartan IP 40 mg Hydrochlorothiazide IP 12.5 mg	1 Tablet	M/s Swiss Garnier Life Sciences / M/s SRK Puremed LLP	7.52
10	Cefixime & Ofloxacin Oral Suspension	Each 5ml of reconstituted suspension contains: Cefixime trihydrate IP eq to Cefixime anhydrous 50mg Ofloxacin IP 50mg	1 ml	M/s Prosperity Drugs Private Limited/ M/s Cachet Pharmaceuticals Pvt. Ltd.	1.74
11	Teneligliptin, Dapagliflozin, Metformin (Sustained Release) Tablets	Each film-coated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20 mg Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10 mg Metformin Hydrochloride IP 500 mg (As Sustained Release)	1 Tablet	M/s Synokem Lifesciences Pvt. Ltd / M/s Glenmark Pharmaceuticals Ltd.	12.15

5. Agenda item no. 5 - Price fixation of 3 products as per Pharmaceuticals Purchase Policy (PPP) for products of Pharma Central Public Sector Enterprises (CPSEs) and their subsidiaries.

5.1 Record Note of Discussion.

The meeting ended with a vote of thanks to the Chair and all the participants in the meeting.


(Sai Ahladini Panda)
 Member Secretary